reports
IRADIMED CORPORATION to Present at the 43rd Annual J.P. Morgan Healthc...
IRADIMED CORPORATION to Present at the 43rd Annual J.P. Morgan Healthcare Conference WINTER SPRINGS, Fla., Dec. 19, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (“MRI”) compatible medical devices and the only provider of a non-magnetic intravenous (“IV”) infusion pump system announced today that Roger Susi, Chief Executive Officer and Jack Glenn, Chief Financial Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference. The Company presentation will take place on Wednesday, Janua...
IRADIMED CORPORATION on Forbes’ List of America’s Most Successful Smal...
IRADIMED CORPORATION on Forbes’ List of America’s Most Successful Small-Cap Companies for 2025 WINTER SPRINGS, Fla., Dec. 10, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), today announced it has been ranked 24th on Forbes’ list of America’s Most Successful Small-Cap Companies 2025. Iradimed is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only provider of a non-magnetic intravenous (“IV”) infusion pump system and non-magnetic patient vital signs monitoring systems that are designed for use during MRI ...
Iradimed Corp: 1 director
A director at Iradimed Corp sold 2,500 shares at 54.180USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
IRADIMED CORPORATION Named to Fortune’s 100 Fastest Growing Companies ...
IRADIMED CORPORATION Named to Fortune’s 100 Fastest Growing Companies List for 2024 WINTER SPRINGS, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) was recently named one of Fortune’s 100 Fastest Growing Companies for 2024. Iradimed is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures. “Being recognized by Fortune as o...
IRADIMED CORPORATION Announces Third Quarter of 2024 Financial Results...
IRADIMED CORPORATION Announces Third Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share Reports record revenue of $18.3 million for the third quarter of 2024, an increase of $1.8 million or 11% over the comparable period 2023.Reports GAAP diluted EPS of $0.40 and Non-GAAP diluted EPS of $0.43 for the third quarter of 2024.Raising year end guidance on GAAP diluted earnings per share to $1.49 to $1.52 from $1.37 to $1.47, and Non-GAAP diluted earnings per share to $1.64 to $1.67 from $1.52 to $1.62. Declares a regular quarterly cash...
IRADIMED CORPORATION to Participate in the 3rd Annual ROTH Healthcare ...
IRADIMED CORPORATION to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference WINTER SPRINGS, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today that it will participate in the 3rd Annual ROTH Healthcare Opportunities Conference. Iradimed’s CFO, Jack Glenn, will host one-on-one meetings with investors at the 3rd Annual ROTH Healthcare Opportunities Conference at the Metropolitan Club in New York on October 9, 2024. About I...
IRADIMED CORPORATION To Participate in the Lake St. Annual Best Ideas ...
IRADIMED CORPORATION To Participate in the Lake St. Annual Best Ideas Growth “Big 8” Investor Conference WINTER SPRINGS, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today that the Company will be participating in the Lake Street 8th Annual Best Ideas Growth "Big 8" Conference. Iradimed management will host one-on-one meetings between company management and investors at the Lake Street 8th Annual Best Ideas Growth "Big 8" Conference at the ...
IRADIMED CORPORATION Announces Second Quarter of 2024 Financial Result...
IRADIMED CORPORATION Announces Second Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share Reports record revenue of $17.9 million for the second quarter of 2024, an increase of 11.2 percent over the comparable period 2023.Reports GAAP diluted EPS of $0.38 and non-GAAP diluted EPS of $0.42 for the second quarter of 2024.Reports second quarter of 2024 operating income of $5.6 million, an increase of 13.4 percent compared to the comparable period of 2023. Declares a regular quarterly cash dividend of $0.15 per common share for the thi...
IRADIMED CORPORATION to Hold 2024 Second Quarter Financial Results Con...
IRADIMED CORPORATION to Hold 2024 Second Quarter Financial Results Conference Call on August 1st Winter Springs, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 second quarter financial results before the market opens on Thursday, August 1, 2024. Iradimed management will host a conference call the same day beginning at 12:00 p.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, . Once registered, a d...
IRADIMED CORPORATION Announces Uplisting to The Nasdaq Global Market
IRADIMED CORPORATION Announces Uplisting to The Nasdaq Global Market Trading to commence effective on the market open June 14, 2024 WINTER SPRINGS, Fla., June 07, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today its common stock will uplist and commence trading on the Nasdaq Global Market, effective June 14, 2024, and will continue under the ticker symbol “IRMD.” Stockholders are not required to take any action due to the uplisting. Roger Susi, Preside...
IRADIMED CORPORATION Announces First Quarter of 2024 Financial Results...
IRADIMED CORPORATION Announces First Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share Reports record revenue of $17.6 million for the first quarter of 2024.Reports GAAP diluted EPS of $0.32 and non-GAAP diluted EPS of $0.36 for the first quarter of 2024.Reports first quarter of 2024 operating income of $4.7 million, an increase of 18.5 percent compared to the same period in 2023.Declares a regular quarterly cash dividend of $0.15 per common share for the second quarter of 2024, payable May 30, 2024. WINTER SPRINGS, Fla., May ...
IRADIMED CORPORATION to Hold 2024 First Quarter Financial Results Conf...
IRADIMED CORPORATION to Hold 2024 First Quarter Financial Results Conference Call on May 2nd WINTER SPRINGS, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 first quarter financial results before the market opens on Thursday, May 2, 2024. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, . Once registered, a dial-i...
IRADIMED CORPORATION To Participate at the 36th Annual Roth Conference
IRADIMED CORPORATION To Participate at the 36th Annual Roth Conference WINTER SPRINGS, Fla., March 13, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced that Roger Susi, the Company's President and Chief Executive Officer, will present at the 36th Annual Roth Conference in Laguna Niguel, CA. Mr. Susi is scheduled for a live fireside chat on Tuesday, March 19, at 12:30 p.m. PT. A live webcast and a replay of the fireside chat will be available on Iradimed’s Investor page at . This year’s event will consist of 1-on-1 / small group meetings, analy...
IRADIMED CORPORATION Announces Fourth Quarter of 2023 and Full Year of...
IRADIMED CORPORATION Announces Fourth Quarter of 2023 and Full Year of 2023 Financial Results Reports record revenue of $17.5 million for the fourth quarter and $65.6 million for the full year of 2023. Reports GAAP diluted EPS of $0.36 and non-GAAP diluted EPS of $0.39 for the fourth quarter of 2023. Reports GAAP diluted EPS of $1.35 and non-GAAP diluted EPS of $1.48 for the full year of 2023. Reports fourth quarter of 2023 operating income of $5.2 million, an increase of 21.3%, compared to the same period in 2022 and full-year operating income of $20.0 million, an increase of 28.2%, com...
IRADIMED CORPORATION to Hold 2023 Fourth Quarter Financial Results Con...
IRADIMED CORPORATION to Hold 2023 Fourth Quarter Financial Results Conference Call on February 8th. WINTER SPRINGS, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2023 fourth quarter financial results before the market opens on Thursday, February 8, 2024. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, .Once registered, ...
IRADIMED CORPORATION Reports Unaudited Fourth Quarter and 2023 Revenue
IRADIMED CORPORATION Reports Unaudited Fourth Quarter and 2023 Revenue Reports preliminary fourth quarter 2023 revenue of $17.5 million WINTER SPRINGS, Fla., Jan. 09, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leader in developing innovative Magnetic Resonance Imaging (‘MRI”) compatible medical devices, today reported unaudited revenue for the fourth quarter and fiscal year ended December 31, 2023. The fourth-quarter revenue totaled approximately $17.5 million, bringing revenue for 2023 to approximately $65.6 million, up 23% from the prior year. “We...
IRADIMED CORPORATION To Present at the 42nd Annual J.P. Morgan Healthc...
IRADIMED CORPORATION To Present at the 42nd Annual J.P. Morgan Healthcare Conference WINTER SPRINGS, Fla., Jan. 02, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leader in developing innovative Magnetic Resonance Imaging (“MRI”) compatible medical devices, today announced that the Company will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference. Iradimed’s CEO, Roger Susi, is scheduled to present on Thursday, January 11, 2024, at 12:00 p.m. Pacific Time. Interested parties may access a live and archived webcast of the prese...
IRADIMED CORPORATION Announces Establishment of a Quarterly Dividend o...
IRADIMED CORPORATION Announces Establishment of a Quarterly Dividend of $0.15 per share and a Special Cash Dividend of $0.48 per share WINTER SPRINGS, Fla., Dec. 12, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD) announced today that its Board of Directors approved a special cash dividend of $0.48 per share and the initiation of a regular quarterly dividend on the Company's outstanding common stock. The regular quarterly dividend is $0.15 per share. The special cash dividend and the quarterly dividend are payable on January 12, 2024, to shareholders of record...
IRADIMED CORPORATION Named a 2024 Most Successful Small-Cap Company in...
IRADIMED CORPORATION Named a 2024 Most Successful Small-Cap Company in America by Forbes WINTER SPRING, Fla., Nov. 30, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) was recently named on Forbes’ latest list of America’s Most Successful Small-Cap Companies for 2024. Iradimed is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures. ...
IRADIMED CORPORATION Announces Third Quarter 2023 Financial Results
IRADIMED CORPORATION Announces Third Quarter 2023 Financial Results Reports record revenue of $16.5 million for the third quarter of 2023.GAAP diluted EPS of $0.40 and non-GAAP diluted EPS of $0.43.Third quarter operating income of $5.9 million, an increase of 43% compared to the same period in 2022. WINTER SPRINGS, Fla., Nov. 03, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) announced today its financial results for the three and nine months ended September 30, 2023. The Company is a leader in the development of innovative magnetic resonance imaging (“...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.